It is an oligonucleotide that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.
Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet41 (4): 255–60. PMID11978144.
Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID11931781.
Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care4 (10): 14–6. PMID11365956.